Just – Evotec Biologics, launched a long-term tech partnership with Sandoz for the immediate development and manufacturing of biosimilars
EIB has granted Evotec an unsecured Loan facility of € 150 m to support the company’s R&D activities, equity investments and the building of the…
Just–Evotec Biologics has been awarded for its flexible cGMP biomanufacturing plant J.POD. The CPhI Award for Manufacturing Technology and Equipment honors innovation in technologies, products,…
Just–Evotec Biologics will support the DOD with rapid, cost-efficient development of safe, efficacious anti-plague mabs. Evotec will provide pre-clinical and clinical trial services.
J.POD® Toulouse, France (EU) Brings a disruptive, flexibly scalable biologics manufacturing technology to the region. The manufacturing facility is expected to be operational in H2…
Just–Evotec Biologics will apply its fully integrated technology platform to develop an optimized commercial process for ALPN-303, a dual BAFF/APRIL inhibitor for systemic lupus erythematosus…
Under the € 7.5 m grant, Evotec will use clinical material manufactured within its Just – Evotec Biologics manufacturing platform to initiate the clinical development…
J.POD® 1 US provides uniquely flexible cGMP manufacturing of kilograms to metric tons of biologics therapeutics J.POD facility expands Just – Evotec Biologics’ capabilities into commercial…
J.POD® 2 EU biomanufacturing will play a key role in addressing the need for therapeutic antibodies, including those related to infectious diseases such as COVID-19
Just – Evotec Biologics’ Redmond, Washington site offers true meaning to “Facility of the Future” with flexible and podular manufacturing of clinical and commercial-stage biologics.…
Just – Evotec Biologics will manufacture anti-SARS-CoV-2 and other antibodies at its J.POD® manufacturing facility. Access to manufacturing capacity over a period of 7 years
Evotec gains access to Alloy Therapeutics’ ATX-Gx™ humanised mouse platform for biologics discovery Partnership leverages complementary strengths of in silico, in vitro and in vivo…